Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes

Placebo-controlled trials of sodium-glucose cotransporter-2 inhibitors (SGLT2i) demonstrate kidney and cardiovascular benefits for people with type 2 diabetes (T2D) and chronic kidney disease (CKD). We used real-world data to compare the kidney and cardiovascular effectiveness of empagliflozin to dipeptidyl peptidase-4 inhibitors (DPP4i), a commonly prescribed antiglycemic medication, in a diverse population with and without CKD. Using electronic health record data from 20 large US health systems, we leveraged propensity overlap weighting to compare outcomes for empagliflozin and DPP4i initiators with T2D between 2016 and 2020.

Source: The American Journal of Cardiology - April 17, 2024 Category: Cardiology Authors: Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, Karen Chiswell, Zachary Lampron, Christina Shay, Keith Marsolo, W. Schuyler Jones, Javed Butler, Raj C. Shah, Alanna M. Chamberlain, Daniel E. Ford, Howard S. Gordon, Wenke Hwang, Alexander Chang, Ajaykum Source Type: research